A new abstract published in JAC-Antimicrobial Resistance demonstrates that the Lodestar DX UTI testing system can ‘accurately identify the common uropathogens present in 87% of mixed cultures’.
The abstract, written by a team led by Stuart Drazich-Taylor at Norfolk and Norwich University Hospitals, was based on a poster presentation given at the British Society for Antimicrobial Chemotherapy Winter Conference held on 4-5 December 2024.
The evaluation looked at 35 heavily contaminated patient samples from 241 selected for analysis and concluded that “in clinical scenarios where the growth is deemed significant, Lodestar DX is able to accurately identify the common uropathogens present.”
Download the poster here: BSAC Poster FINAL 2
Read the full abstract here: https://tinyurl.com/y9x7bnuw
The Lodestar DX analyser and testing system is registered with the European Patent Office (European Patent Application no: 22732302.9) and the US Patent and Trademark Office (no.18/558,490).